


Catalog # 10-2768

Pomalidomide

CAS# 19171-19-8

1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide

Lot # X109653



Thalidomide analog. Inhibits cereblon (CRBN) an E3 ubiquitin ligase, IC₅₀ ~3 μM for CRBN-DDB1 complex.¹ Displays antiangiogenic and immunomodulatory activity *in vivo* potently inhibiting the production of TNFα and IL-2.² Promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.³ Conjugation with other ligands is a strategy to target proteins for *in vivo* proteasomal degradation via PROTACS.^{4,5}

- 1) Lopez-Girona *et al.* (2012), *Cereblon is direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide*; *Leukemia*, **26** 2326
- 2) Zhu *et al.* (2013), *Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma*; *Leukemia Lymphoma*, **54** 683
- 3) Donovan *et al.* (2018), *Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome*; *Elife*, **7** e38430
- 4) Winter *et al.* (2015), *DRUG DEVELOPMENT. Phthalimide conjunction as a strategy for in vivo target protein degradation*; *Science*, **348** 1376
- 5) Lohbeck and Miller (2016), *Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development*; *Bioorg. Med. Chem. Lett.*, **26** 5260

PHYSICAL DATA

Molecular Weight:	273.24
Molecular Formula:	C ₁₃ H ₁₁ N ₃ O ₄
Purity:	98% by TLC
	NMR: (Conforms)
Solubility:	DMSO (up to 50 mg/ml)
Physical Description:	Yellow solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.